We are live on ! Find out more
CPRX

Catalyst Pharmaceutical
CPRX

Delisted

CPRX was delisted on the 14th of July, 2026.

Back to rankings

69 hedge funds and large institutions have $93.7M invested in Catalyst Pharmaceutical in 2017 Q2 according to their latest regulatory filings, with 27 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed

894% more call options, than puts

Call options by funds: $1.08M | Put options by funds: $109K

286% more first-time investments, than exits

New positions opened: 27 | Existing positions closed: 7

90% more capital invested

Capital invested by funds: $49.3M → $93.7M (+$44.4M)

42% more repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 12

38% more funds holding

Funds holding: 50 → 69 (+19)

10.01% more ownership

Funds ownership: 30.5% → 40.51% (+10%)

Holders
69
Holders Change
+19
Holders Change %
+38%
% of All Funds
1.72%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
27
Increased
17
Reduced
12
Closed
7
Calls
$1.08M
Puts
$109K
Net Calls
+$974K
Net Calls Change
+$562K

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$6.33M
2
JP Morgan Chase
JP Morgan Chase
New York
+$3.04M
3
State Street
State Street
Massachusetts
+$1.86M
4
Northern Trust
Northern Trust
Illinois
+$1.44M
5
KCM
Kennedy Capital Management
Missouri
+$1.44M

Top Sellers

Rank Fund Capital Flow
1
BC
Broadfin Capital
New York
-$1.77M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$1.71M
3
CA
Corrado Advisors
New Jersey
-$239K
4
BFM
Boothbay Fund Management
New York
-$140K
5
CS
Candriam SCA
Luxembourg
-$83.5K
Name Holding Trade Value Shares
Change 		Change in
Stake
OAM
26
Oxford Asset Management
United Kingdom
$238K +$56.8K +27,228 +46%
VKH
27
Virtu KCG Holdings
New York
$237K +$179K +85,907 New
RhumbLine Advisers
28
RhumbLine Advisers
Massachusetts
$209K +$158K +75,701 New
BFM
29
Boothbay Fund Management
New York
$190K -$140K -66,902 -49%
Manulife (Manufacturers Life Insurance)
30
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$175K +$125K +59,896 +1,861%
Squarepoint
31
Squarepoint
New York
$167K +$126K +60,500 New
WMSA
32
Weiss Multi-Strategy Advisers
New York
$166K -$16.7K -8,000 -12%
State of Wisconsin Investment Board
33
State of Wisconsin Investment Board
Wisconsin
$149K +$113K +54,000 New
AIG
34
American International Group
New York
$122K +$92.6K +44,379 New
California Public Employees Retirement System
35
California Public Employees Retirement System
California
$114K – – –
New York State Common Retirement Fund
36
New York State Common Retirement Fund
New York
$114K +$86.4K +41,400 New
NFA
37
Nationwide Fund Advisors
Ohio
$111K +$83.8K +40,137 New
VOYA Investment Management
38
VOYA Investment Management
Georgia
$91K +$68.8K +32,973 New
GC
39
Guggenheim Capital
Illinois
$74K +$4.68K +2,242 +9%
FAAS
40
First Allied Advisory Services
California
$72K +$54.3K +26,000 New
Commonwealth Equity Services
41
Commonwealth Equity Services
Massachusetts
$66K -$574 -275 -1%
Millennium Management
42
Millennium Management
New York
$62K -$78.3K -37,503 -62%
HSA
43
HBK Sorce Advisory
Pennsylvania
$58K +$44.1K +21,109 New
MCC
44
Malaga Cove Capital
California
$56K – – –
PMG
45
ProVise Management Group
Florida
$52K – – –
Goldman Sachs
46
Goldman Sachs
New York
$52K +$413 +198 +1%
Russell Investments Group
47
Russell Investments Group
United Kingdom
$49K +$36.9K +17,696 New
Barclays
48
Barclays
United Kingdom
$44K +$33.6K +16,079 New
RJFSA
49
Raymond James Financial Services Advisors
Florida
$43K – – –
CS
50
Credit Suisse
Switzerland
$38K -$4.32K -2,071 -13%
1
2
3 4

CPRX Hedge Fund Activity: Q2 2017 in Review

69 of the 4,011 institutional investors tracked by Wall St. Rank reported a position in Catalyst Pharmaceutical (CPRX) for Q2 2017, worth a combined $93.7M — up 90% from $49.3M a quarter earlier.

Buyers outnumbered sellers: 27 funds opened new CPRX positions and 7 closed out — a net gain of 20 holders — while 17 added to existing stakes and 12 trimmed.

The largest buyer was BlackRock, adding an estimated $6.33M. The largest seller was Broadfin Capital, cutting an estimated $1.77M.

  • 69 institutional investors held Catalyst Pharmaceutical (CPRX) as of Q2 2017, up from 50 in Q1 2017.
  • Funds reported $93.7M of Catalyst Pharmaceutical stock for Q2 2017, up 90% quarter-over-quarter.
  • 27 funds opened new Catalyst Pharmaceutical positions in Q2 2017 and 7 closed out, a net change of +20 holders.
  • The largest Catalyst Pharmaceutical buyer in Q2 2017 was BlackRock, an estimated $6.33M added.
  • The largest Catalyst Pharmaceutical seller in Q2 2017 was Broadfin Capital, an estimated $1.77M sold.

Based on aggregated 13F filings for Q2 2017.